Early aggressive immunosuppressive regimens have fundamentally changed the treatment and management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV). However, how to maintain remission in these patients is debated. Here, Raashid Luqmani considers how best to achieve maintenance of clinical remission in patients with AAV.